Gladius Pharmaceuticals Overview

  • Founded

  • 2015

Founded
  • Status

  • Out of Business

  • Employees

  • 6

Employees
  • Latest Deal Type

  • Out of Business

Gladius Pharmaceuticals General Information

Description

Developer of antibiotics intended to assist in the empiric treatment of gram-negative infections. The company's antibiotics have demonstrated broad-spectrum efficacy against gram-negative pathogens and are capable of replacing older generation cephalosporins, enabling physicians to treat bacterial infections effectively.

Contact Information

Website
www.gladiuspharma.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 500 Boulevard Cartier Ouest
  • Laval, Quebec H7V 5B7
  • Canada
+1 (514) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gladius Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 03-May-2022 00.000 Completed Out of Business
2. Early Stage VC 27-Nov-2018 00.000 00.000 Completed Generating Revenue
1. Early Stage VC (Series A) 24-Jun-2015 $3.33M $3.33M Completed Startup
To view Gladius Pharmaceuticals’s complete valuation and funding history, request access »

Gladius Pharmaceuticals Patents

  • 34

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Gladius Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190100534-A1 Cephem compounds with latent reactive groups Inactive 04-Oct-2017 0000000000 00
CA-2905240-A1 Derivatized 3-styryl-cephalosporins Inactive 12-Mar-2013 0000000000
EP-2968352-A4 Derivatized 3-styryl-cephalosporins Active 12-Mar-2013 0000000000 0
EP-3441071-A1 Derivatized cephalosporins Inactive 12-Mar-2013 0000000000 0
EP-2968352-A2 Derivatized 3-styryl-cephalosporins Active 12-Mar-2013 C07D501/60
To view Gladius Pharmaceuticals’s complete patent history, request access »

Gladius Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial